TY  - JOUR
AU  - Rényi-Vámos, Ferenc István
AU  - Tóth, Imre
AU  - Takács, István
TI  - A Belügyminisztérium egészségügyi szakmai irányelve a pyothorax (gennymell) ellátásáról
JF  - EGÉSZSÉGÜGYI KÖZLÖNY
J2  - EGÉSZSÉGÜGYI KÖZLÖNY
VL  - 73
PY  - 2023
IS  - 22
SP  - 1992
EP  - 2003
PG  - 12
SN  - 2063-1146
UR  - https://m2.mtmt.hu/api/publication/34451774
ID  - 34451774
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Takács, István
AU  - Enyedi, Attila
AU  - Váradi, Csongor
AU  - Kóder, Gergely
AU  - Mudriczki, Gábor
AU  - Tóth, Dezső
TI  - A debreceni mellkassebészet: múlt és jelen
JF  - MAGYAR SEBÉSZET
J2  - MAGYAR SEBÉSZET
VL  - 75
PY  - 2022
IS  - 1
SP  - 67
EP  - 74
PG  - 8
SN  - 0025-0295
DO  - 10.1556/1046.2021.10014
UR  - https://m2.mtmt.hu/api/publication/33561437
ID  - 33561437
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Tóth, László József
AU  - Varga, Imre
AU  - Valkó, Boglárka
AU  - Takács, István
AU  - Váradi, Csongor
AU  - Kóder, Gergely
AU  - Garai, Ildikó
AU  - Endes, Gábor
AU  - Méhes, Gábor
TI  - Pigmentált orsósejtes carcinoid : esetismertetés
JF  - MEDICINA THORACALIS (BUDAPEST)
J2  - MED THORAC (BP)
VL  - 75
PY  - 2022
IS  - 3
SP  - 219
SN  - 0238-2571
UR  - https://m2.mtmt.hu/api/publication/33367813
ID  - 33367813
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Tóth, László József
AU  - Enyedi, Attila
AU  - Takács, István
AU  - Mudriczki, Gábor
AU  - Brugós, László
AU  - Vaskó, Attila
AU  - Endes, Gábor
AU  - Mokánszky, Attila
AU  - Méhes, Gábor
TI  - Sclerotizáló pneumocyta előfordulása anyagunkban - 4 eset klinikopatológiai bemutatása
JF  - MEDICINA THORACALIS (BUDAPEST)
J2  - MED THORAC (BP)
VL  - 75
PY  - 2022
IS  - 3
SP  - 218
EP  - 219
PG  - 2
SN  - 0238-2571
UR  - https://m2.mtmt.hu/api/publication/33367760
ID  - 33367760
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Tóth, László József
AU  - Takács, István
AU  - Váradi, Csongor
AU  - Kóder, Gergely
AU  - Kardos, Tamás
AU  - Endes, Gábor
AU  - Orlik, Brigitta
AU  - Baráth, Lukács
AU  - Méhes, Gábor
TI  - Óriássejtes csonttumor tüdőáttétei : esetismertetés
JF  - MEDICINA THORACALIS (BUDAPEST)
J2  - MED THORAC (BP)
VL  - 75
PY  - 2022
IS  - 3
SP  - 218
SN  - 0238-2571
UR  - https://m2.mtmt.hu/api/publication/33334286
ID  - 33334286
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Kovács, Árpád
AU  - Csiki, Emese
AU  - Lieber, Attila
AU  - Takács, István
AU  - Bittner, Nóra
AU  - Trási, Krisztina
AU  - Papp, Judit
AU  - Simon, Mihály
TI  - Korai stadiumú tüdő NSCLC betegek modern ellátása. A DE KK 5 éves korai eredményei klasszikus műtét és SBRT összevetésében
JF  - MEDICINA THORACALIS (BUDAPEST)
J2  - MED THORAC (BP)
VL  - 75
PY  - 2022
IS  - 3
SP  - 167
EP  - 168
PG  - 2
SN  - 0238-2571
UR  - https://m2.mtmt.hu/api/publication/33334280
ID  - 33334280
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Szántó, Erika
AU  - Bittner, Nóra
AU  - Dér, Ádám
AU  - Csiki, Emese
AU  - Besenyői, Mária
AU  - Barta, Zsuzsanna
AU  - Simon, Mihály
AU  - Fodor, Andrea
AU  - Orosz, Zsuzsanna Zita
AU  - Takács, István
AU  - Kovács, Árpád
TI  - Nem kissejtes tüdőrákos betegek durvalumab kezeléssel kiegészített kemoradioterápiájával szerzett kezdeti tapasztalatok
JF  - MEDICINA THORACALIS (BUDAPEST)
J2  - MED THORAC (BP)
VL  - 75
PY  - 2022
IS  - 3
SP  - 166
EP  - 167
PG  - 2
SN  - 0238-2571
UR  - https://m2.mtmt.hu/api/publication/33334276
ID  - 33334276
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Makai, Attila
AU  - Kovács, Tamás
AU  - Lieber, Attila
AU  - Kardos, Tamás
AU  - Orosz, Zsuzsanna Zita
AU  - Vaskó, Attila
AU  - Bittner, Nóra
AU  - Takács, István
TI  - Nintedanib kezelés 4 év távlatában
JF  - MEDICINA THORACALIS (BUDAPEST)
J2  - MED THORAC (BP)
VL  - 75
PY  - 2022
IS  - 3
SP  - 159
SN  - 0238-2571
UR  - https://m2.mtmt.hu/api/publication/33334273
ID  - 33334273
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Fagyas, Miklós
AU  - Bánhegyi, Viktor
AU  - Úri, Katalin
AU  - Enyedi, Attila
AU  - Lizanecz, Erzsébet
AU  - Mányiné Siket, Ivetta
AU  - Mártha, L
AU  - Fülöp, Gábor Áron
AU  - Radovits, Tamás
AU  - Pólos, Miklós
AU  - Merkely, Béla Péter
AU  - Kovács, Árpád
AU  - Szilvássy, Zoltán
AU  - Ungvári, Zoltán István
AU  - Édes, István
AU  - Csanádi, Zoltán
AU  - Boczán, Judit
AU  - Takács, István
AU  - Szabó, G
AU  - Balla, József
AU  - Balla, György
AU  - Seferovic, P
AU  - Papp, Zoltán
AU  - Tóth, Attila
TI  - Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients
JF  - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)
J2  - GEROSCIENCE
VL  - 43
PY  - 2021
IS  - 5
SP  - 2289
EP  - 2304
PG  - 16
SN  - 2509-2715
DO  - 10.1007/s11357-021-00467-2
UR  - https://m2.mtmt.hu/api/publication/32301518
ID  - 32301518
N1  - * Megosztott szerzőség
AB  - Angiotensin-converting enzyme 2 (ACE2) is essential for SARS-CoV-2 cellular entry. Here we studied the effects of common comorbidities in severe COVID-19 on ACE2 expression. ACE2 levels (by enzyme activity and ELISA measurements) were determined in human serum, heart and lung samples from patients with hypertension (n = 540), heart transplantation (289) and thoracic surgery (n = 49). Healthy individuals (n = 46) represented the controls. Serum ACE2 activity was increased in hypertensive subjects (132%) and substantially elevated in end-stage heart failure patients (689%) and showed a strong negative correlation with the left ventricular ejection fraction. Serum ACE2 activity was higher in male (147%), overweight (122%), obese (126%) and elderly (115%) hypertensive patients. Primary lung cancer resulted in higher circulating ACE2 activity, without affecting ACE2 levels in the surrounding lung tissue. Male sex resulted in elevated serum ACE2 activities in patients with heart transplantation or thoracic surgery (146% and 150%, respectively). Left ventricular (tissular) ACE2 activity was unaffected by sex and was lower in overweight (67%), obese (62%) and older (73%) patients with end-stage heart failure. There was no correlation between serum and tissular (left ventricular or lung) ACE2 activities. Neither serum nor tissue (left ventricle or lung) ACE2 levels were affected by RAS inhibitory medications. Abandoning of ACEi treatment (non-compliance) resulted in elevated blood pressure without effects on circulating ACE2 activities. ACE2 levels associate with the severity of cardiovascular diseases, suggestive for a role of ACE2 in the pathomechanisms of cardiovascular diseases and providing a potential explanation for the higher mortality of COVID-19 among cardiovascular patients. Abandoning RAS inhibitory medication worsens the cardiovascular status without affecting circulating or tissue ACE2 levels.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bánhegyi, Viktor
AU  - Enyedi, Attila
AU  - Fülöp, Gábor Áron
AU  - Oláh, Attila
AU  - Mányiné Siket, Ivetta
AU  - Váradi, Csongor
AU  - Bottyán, Klaudia
AU  - Lódi, Mária
AU  - Csongrádi, Alexandra
AU  - Umar, Azeem J.
AU  - Fagyas, Miklós
AU  - Czuriga, Dániel
AU  - Édes, István
AU  - Pólos, Miklós
AU  - Merkely, Béla Péter
AU  - Csanádi, Zoltán
AU  - Papp, Zoltán
AU  - Szabó, Gábor
AU  - Radovits, Tamás
AU  - Takács, István
AU  - Tóth, Attila
TI  - Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart
JF  - CELLS
J2  - CELLS-BASEL
VL  - 10
PY  - 2021
IS  - 7
PG  - 13
SN  - 2073-4409
DO  - 10.3390/cells10071708
UR  - https://m2.mtmt.hu/api/publication/32113758
ID  - 32113758
N1  - Takács István és Tóth Attila megosztott utolsó szerzők
AB  - Objective: Inhibitors of the angiotensin converting enzyme (ACE) are the primarily chosen drugs to treat heart failure and hypertension. Moreover, an imbalance in tissue ACE/ACE2 activity is implicated in COVID-19. In the present study, we tested the relationships between circulating and tissue (lung and heart) ACE levels in men. Methods: Serum, lung (n = 91) and heart (n = 72) tissue samples were collected from Caucasian patients undergoing lung surgery or heart transplantation. ACE I/D genotype, ACE concentration and ACE activity were determined from serum and tissue samples. Clinical parameters were also recorded. Results: A protocol for ACE extraction was developed for tissue ACE measurements. Extraction of tissue-localized ACE was optimal in a 0.3% Triton-X-100 containing buffer, resulting in 260 ± 12% higher ACE activity over detergent-free conditions. SDS or higher Triton-X-100 concentrations inhibited the ACE activity. Serum ACE concentration correlated with ACE I/D genotype (II: 166 ± 143 ng/mL, n = 19, ID: 198 ± 113 ng/mL, n = 44 and DD: 258 ± 109 ng/mL, n = 28, p < 0.05) as expected. In contrast, ACE expression levels in the lung tissue were approximately the same irrespective of the ACE I/D genotype (II: 1423 ± 1276 ng/mg, ID: 1040 ± 712 ng/mg and DD: 930 ± 1273 ng/mg, p > 0.05) in the same patients (values are in median ± IQR). Moreover, no correlations were found between circulating and lung tissue ACE concentrations and activities (Spearman’s p > 0.05). In contrast, a significant correlation was identified between ACE activities in serum and heart tissues (Spearman’s Rho = 0.32, p < 0.01). Finally, ACE activities in lung and the serum were endogenously inhibited to similar degrees (i.e., to 69 ± 1% and 53 ± 2%, respectively). Conclusion: Our data suggest that circulating ACE activity correlates with left ventricular ACE, but not with lung ACE in human. More specifically, ACE activity is tightly coordinated by genotype-dependent expression, endogenous inhibition and secretion mechanisms.
LA  - English
DB  - MTMT
ER  -